Browsing Tag
Dupilumab
5 posts
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.
What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy.
Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission…
Dupixent delivers positive results in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of…
Dupixent receives FDA approval for treatment of moderate-to-severe asthma
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration…